SCHEMBL3379944

SCHEMBL3379944

CC(C)(C)OC(=O)c1cccc(N(Cc2ccccc2)S(=O)(=O)c2ccc(F)cc2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.55
NR3C1 P04150 1/20 0.53
LMNA P02545 3/20 0.52
ALDH1A1 P00352 1/20 0.52
KMT2A Q03164 5/20 0.52
MEN1 O00255 4/20 0.52
L3MBTL1 Q9Y468 1/20 0.51
ESR1 P03372 1/20 0.48
POLB P06746 1/20 0.48
GAA P10253 1/20 0.47
HTT P42858 1/20 0.47
PSEN1 P49768 1/20 0.47
PSEN2 P49810 1/20 0.47
APH1B Q8WW43 1/20 0.47
NCSTN Q92542 1/20 0.47
APH1A Q96BI3 1/20 0.47
PSENEN Q9NZ42 1/20 0.47
TAS2R14 Q9NYV8 1/20 0.47
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3376969 0.93 LMNA (0.60) MAPTNR3C1LMNAALDH1A1KMT2A
SCHEMBL3378945 0.91 LMNA (0.56) MAPTLMNAALDH1A1KMT2AMEN1
SCHEMBL3374481 0.88 KCNA5 (0.49) MAPTLMNAALDH1A1KMT2AMEN1
SCHEMBL2192252 0.85 LMNA (0.71) MAPTNR3C1LMNAALDH1A1KMT2A
SCHEMBL3376355 0.84 KMT2A (0.50) LMNAALDH1A1KMT2AMEN1L3MBTL1
SCHEMBL3379849 0.83 MAPT (0.59) MAPTNR3C1LMNAALDH1A1KMT2A
SCHEMBL3376926 0.82 MAPT (0.60) MAPTNR3C1LMNAALDH1A1KMT2A
SCHEMBL3275261 0.80 PTGES (0.59) NR3C1LMNAALDH1A1L3MBTL1ESR1
SCHEMBL2214077 0.80 LMNA (0.46) MAPTLMNAALDH1A1KMT2AMEN1
SCHEMBL3380883 0.79 LMNA (0.43) MAPTLMNAALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP disclosed
US-9447033-B2 Potassium channel blockers JAPAN TOBACCO INC. (JP) 2016-09-20 US disclosed
US-20150259282-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2015-09-17 US disclosed
US-9073834-B2 Potassium channel blockers XENTION LIMITED (GB) 2015-07-07 US disclosed
US-20140221337-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2014-08-07 US disclosed
US-8673901-B2 Potassium channel blockers XENTION LIMITED (GB) 2014-03-18 US disclosed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221337-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 MAPT 2884/4885NR3C1 3992/4885LMNA 1619/4885
US-20100087428-A1 Novel Potassium Channel Blockers HCN4, SCN2B, KCNH2 MAPT 4874/4885NR3C1 265/4885LMNA 2145/4885
US-20150259282-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 MAPT 2884/4885NR3C1 3992/4885LMNA 1619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.